Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics

被引:8
|
作者
Yuan, Heng [1 ]
Jung, Eun-Soo [2 ,3 ,4 ]
Chae, Soo-Wan [2 ,3 ,4 ]
Jung, Su-Jin [2 ,3 ,4 ]
Daily, James W. [5 ]
Park, Sunmin [1 ,6 ]
机构
[1] Hoseo Univ, Dept Bioconvergence, Asan 31499, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[3] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[4] Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju 54907, South Korea
[5] Daily Mfg Inc, Dept R&D, Rockwell, NC 28138 USA
[6] Hoseo Univ, Obes Diabet Res Ctr, Dept Food & Nutr, 20 Hoseoro79 Bungil, Asan 31499, South Korea
关键词
metabolic dysfunction-associated steatotic liver disease; HFFs; gut microbiota; omics approach; HEPATIC STEATOSIS; NONCODING RNAS; DISEASE; PATHOGENESIS; CELLS; INFLAMMATION; CROSSTALK; NAFLD; NASH;
D O I
10.3390/nu16183061
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores the potential of health functional foods (HFFs) to maintain healthy liver function and prevent MASLD through an integrative analysis of network pharmacology, gut microbiota, and multi-omics approaches. We first examined the biomarkers associated with MASLD, emphasizing the complex interplay of genetic, environmental, and lifestyle factors. We then applied network pharmacology to identify food components with potential beneficial effects on liver health and metabolic function, elucidating their action mechanisms. This review identifies and evaluates strategies for halting or reversing the development of steatotic liver disease in the early stages, as well as biomarkers that can evaluate the success or failure of such strategies. The crucial role of the gut microbiota and its metabolites for MASLD prevention and metabolic homeostasis is discussed. We also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, and integrated multi-omics analyses, in research on preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms and potential biomarkers for HFF development. The review concludes by proposing an integrated approach for developing HFFs targeting MASLD prevention, considering the Korean regulatory framework. We outline future research directions that bridge the gap between basic science and practical applications in health functional food development. This narrative review provides a foundation for researchers and food industry professionals interested in developing HFFs to support liver health. Emphasis is placed on maintaining metabolic balance and focusing on prevention and early-stage intervention strategies.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
    Trinks, Julieta
    Mascardi, Maria F.
    Gadano, Adrian
    Marciano, Sebastian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (14) : 1982 - 1989
  • [32] Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease
    Park, In-gyu
    Yoon, Sang Jun
    Won, Sung-min
    Oh, Ki-Kwang
    Hyun, Ji Ye
    Suk, Ki Tae
    Lee, Unjoo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] Multi-omics analysis of the effect and mechanism of sodium-glucose cotransporter 2 inhibitors on metabolic dysfunction-associated fatty liver disease
    Chen, J.
    Du, J.
    Sun, Q.
    Zhang, M.
    Haoming, T.
    DIABETOLOGIA, 2024, 67 : S462 - S462
  • [34] Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
    Umasankari, S.
    Aishwarya, S.
    Aishwarya, S. K.
    Bhardwaj, Shivangi
    Pavithra, R. B.
    Ray, Soumili
    Vinodhini, V. M.
    METABOLISM OPEN, 2024, 24
  • [35] Synergistic Effects of Fructose and Food Preservatives on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Gut Microbiome Alterations to Hepatic Gene Expression
    Hrncir, Tomas
    Trckova, Eva
    Hrncirova, Lucia
    NUTRIENTS, 2024, 16 (21)
  • [36] EFFICACY AND SAFETY OF RESMETIROM IN TREATING PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ekreer, Moad
    Al Hayek, Mohammad
    Alhateem, Mohamed Salah
    Khashan, Abdallah
    Abeedah, Raja
    Aghneewah, Omar
    Abduljawad, Fatimah Alzahra
    Elhadi, Muhammed
    HEPATOLOGY, 2024, 80
  • [37] Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
    Min, Byeong Hyun
    Devi, Shivani
    Kwon, Goo Hyun
    Gupta, Haripriya
    Jeong, Jin-Ju
    Sharma, Satya Priya
    Won, Sung-Min
    Oh, Ki-Kwang
    Yoon, Sang Jun
    Park, Hee Jin
    Eom, Jung A.
    Jeong, Min Kyo
    Hyun, Ji Ye
    Stalin, Nattan
    Park, Tae-Sik
    Choi, Jieun
    Lee, Do Yup
    Han, Sang Hak
    Kim, Dong Joon
    Suk, Ki Tae
    GUT MICROBES, 2024, 16 (01)
  • [38] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [39] Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study
    Damien Denimal
    Maharajah Ponnaiah
    Franck Phan
    Anne-Caroline Jeannin
    Alban Redheuil
    Joe-Elie Salem
    Samia Boussouar
    Pauline Paulstephenraj
    Suzanne Laroche
    Chloé Amouyal
    Agnès Hartemann
    Fabienne Foufelle
    Olivier Bourron
    Cardiovascular Diabetology, 24 (1)
  • [40] Cannabis Use in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Friend or a Foe? Insights From a Nationwide Analysis (2016-2020)
    Paladiya, Ruchir Damjibhai.
    Singh, Anmol
    Shah, Mihir P.
    Kumar, Vikash
    Sohal, Aalam
    Doshi, Shreyans
    Parikh, Neil D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1461 - S1462